Amgen "outperform"

02.03.07 - Robert W. Baird

NEW YORK, March 2 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on Amgen Inc (AMGN). The target price is set to $90.

In a research note published this morning, the analysts mention that the results of the145 trial are unlikely to exhibit any statistically significant benefit or loss for the patients treated with the company?s Aranesp drug. The analysts add, however, that the 145 trial results, scheduled to be announced between April 10 and May 10, are expected to lift the substantial overhang on the company?s stock.